Optical and multi-modal analysis to help diagnose skin cancer
Official title: Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis.
Run by Centre Hospitalier Régional Metz-Thionville · NCT07406022 · Data updated 2026-11-12
This project tests whether combining optical spectroscopy and imaging data from skin samples can help diagnose skin cancer in people with skin concerns.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Centre Hospitalier Régional Metz-Thionville Academic / other |
| Locations | 1 site (Metz) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT07406022 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with skin carcinomas or actinic keratoses seeking diagnostic evaluation.
✕Probably not a fit
Patients without skin lesions or without diagnostic uncertainty may not benefit from this observational data collection.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The OpticSkin project collects and shares a database of histology and optical spectroscopy data from healthy, precancerous, and cancerous skin. It uses methods such as absorption, scattering (including Raman), autofluorescence, and polarization measurements to identify signatures associated with skin cancers. The study emphasizes multi-modality data integration and may involve machine learning to improve diagnostic accuracy. It is observational and aims to complement traditional histology with non-invasive diagnostic information. The work is supported by PEPR LUMA and led by CHR Metz-Thionville, focusing on real-world clinical relevance for skin cancer imaging and diagnosis.
Why it matters
Potential benefit: If successful, the approach could provide additional diagnostic clues to improve accuracy and speed in identifying skin cancer.
How similar studies have gone: Previous work suggests that combining imaging and spectroscopy can improve diagnostic information, though the exact multi-modality approach is novel in this project context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with skin carcinomas and actinic keratoses Exclusion Criteria: * minor patient
Where it's running
-
CHR Metz-Thionville
Metz, France Recruiting
Study contacts
- Study coordinator: Andreia CARVALHO DE FREITAS
- Email: projet-recherche-clinique@chr-metz-thionville.fr
- Phone: 0033387553323
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mobile sun protection support to help young adults stay safe in the sun
This project tests a mobile health program to see if reminders, education, planning tools, and real-time sun exposure information can help young adults protect their skin from excessive sun exposure.
-
Periprosthetic Joint Infection After Hip or Knee Replacement: Causes and Prevention
This study tests whether certain factors before and after hip or knee replacement help predict and prevent peri-implant infections in adults 45 and older.
-
Night-to-night variability of physiological markers in home sleep apnea testing
This study tests how stable both traditional and novel sleep apnea markers are from one night to the next in people undergoing home sleep apnea testing.
-
Psycho-physiological profiling of people with low versus high heat resilience
This project will test whether controlled heat and UV exposures plus physiological and psychological measurements can identify healthy adults who are more or less resilient to heat.
-
Cosibelimab for tough CSCC in kidney transplant recipients or blood cancers
This trial tests cosibelimab in people with advanced cutaneous squamous cell carcinoma who have a kidney transplant or certain blood cancers to see if it is safe and helpful for them.
-
First-line immunotherapy and PD-L1 testing for metastatic melanoma in Slovenia
This study will see if first-line immunotherapy (pembrolizumab, nivolumab, or ipilimumab plus nivolumab) works for adults in Slovenia with metastatic melanoma and whether PD-L1 measurements predict who responds.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.